China has increasingly become a focal point of the global pharmaceutical industry. Rising incomes, improving healthcare infrastructure and enhanced insurance systems have propelled the Chinese pharmaceutical market to become the third-largest in the world.
Fuelled by increasing healthcare demands within its own borders as well as by international companies seeking manufacturing facilities, China's hunger for foreign partnerships and pharmaceutical ingredients presents a great opportunity for international and domestic suppliers and buyers.
The entry of multinational companies has granted local manufacturers access to advanced technologies and further aided market development in the country. In fact, the market in China has already consolidated its strategic position globally with local mergers, acquisitions and joint ventures and investments in private infrastructure are expected to go up significantly.
According to a new analysis from Frost & Sullivan , Chinese pharmaceutical market earned revenues of $131.63 billion in 2012 and estimates this to more than double to $ 280.30 billion in 2016.
"Apart from the opportunities created by government healthcare reforms for essential drug systems as well as medical insurance and primary healthcare solutions, the impending expiry of several drug patents boosts the prospects of local pharmaceutical manufacturers in China," said the analysis.
While government reforms have fuelled market growth, they have also led to challenges in essential drug tendering, market access, and price setting, affecting certain manufacturers' margins in the country.
In this context CPhI China, an event organised by UBM Live and UBM Sinoexpo, which is returning to the Shanghai New International Expo Center for the 13th consecutive year holds special significance. The event is being held from June 25 to 27 with an increased scale, more informative exhibitions and regional networking opportunities and a greater range of content services than it has ever offered before.
"With a view to enhancing the customer experience and ROI value, we have added high value conferences and live laboratory showcases. The Show Daily is being re-launched at this year’s event to assist attendees in staying on the pulse of the day’s events, topical news and product launches, alongside in-depth features and valuable insight across the Chinese pharma market", says Erik Heemskerk, Brand Director for CPhI China.
"Additionally, we have launched a mobile application – available in both Mandarin and English - that keeps attendees connected with all information they need instantly. This application has been designed to free-up the event experience and is a convenient tool to not only navigate around the exhibition, but also to arrange and manage meetings on the go. One final point for this year is an increased focus on R&D with LABWorld, BioPharma and ICSE all contained in one hall", he added.
The event is expected to attract 2,500 exhibitors, and 30,000 visitors from more than 100 countries. It is a unique one-stop platform to meet current partners, build new relationships, evaluate pharmaceutical products and learn about the latest industry trends.
The number of exhibitors has seen a tremendous upsurge thanks to increased Chinese manufacturing opportunities and huge growth in China’s generics sector. This rapid development, coupled with the evolving regulatory landscape is attracting both domestic and international investors to the Chinese market.
CPhI China 2013 is a must attend event for anyone interested in breaking into China’s pharmaceuticals market and establishing Chinese partners.
“In 2012, the size of the Chinese pharmaceutical market reached 926.1 billion RMB, and is expected to expand at an annual rate of 12 per cent from 2013 to 2020” says Nik Rudge, Managing Director at UBM Live.
“Today, leading Chinese CROs and pharmaceutical companies are able to offer high quality, cost-effective services on a global scale with growth rates forecast to far outpace the rest of the industry. The increasing ability of Chinese companies to meet international standards in drug quality and safety, coupled with strong growth in the local market, makes this is a must attend event for any pharmaceutical company in 2013 – whether Chinese, regional or international in focus”, he added.
The co-located events
The co-located events for the 2013 edition are P-MEC China, which covers machinery and equipment; ICSE China, for companies providing outsourcing services in custom synthesis and clinical trials; BioPh China, a dedicated platform for biopharmaceuticals; and InnoPack, focussed on bringing global packaging solutions to the Chinese pharma companies. Additionally, following huge demand in 2012, this year 's co-located events include LABWorld China - which will focus on innovation and new developments, providing a forum for increased education and networking for businesses in the laboratory, analytical and biotech equipment sector.
"As China witnesses growing technology and engineering skills and a rapidly expanding pharmaceutical market, CPhI China’s co-located events provide the ideal platform to generate industry collaborations across multiple areas of the industry – whether attending as a supplier, buyer, investor or researcher", says Erik Heemskerk.
P-MEC China
With more than 320 exhibitors expected, P-MEC China provides a great opportunity to meet pharmaceutical machinery and equipment suppliers and compare their products in one place.
P-MEC China is attracting more and more visitors every year. They include specialists from general management, marketing & sales, purchasing, production, quality control, engineering and R&D. On an average, nearly 70 per cent of all visitors have real purchasing power. Decision-makers from the entire pharmaceutical industry will be searching for new products, services and deals.
P-MEC China is also featuring an Environmental Protection & Clean Tech Area which will focus on clean technology and environmental protection designed to meet the high standards required by pharmaceutical manufacturing.
ICSE China
ICSE connects the pharmaceutical community with outsourcing solution providers, offering a forum for business development, networking and education.
ICSE attracts international exhibitors who are keen to capitalise on the benefits of doing business in China. Besides contract manufacturing and contract research, other main services provided are packaging, clinical trials, laboratory services, drug discovery and marketing services.
ICSE China , the only specific theme exhibition held for the CRO&CMO industry, offers all pharmaceutical companies a one stop CRO&CMO outsourcing procurement platform and an excellent bridge for communication with industry peers and for exchanging latest industry information.
LABWorld China
LABWorld China is a brand-new networking event for any business or individual in the laboratory, analytical & biotech equipment sector. It connects the pharmaceutical community active in laboratory, analytical & biotechnology instrumentation, offering a forum for business development, networking & education.
With a focus on innovation and new developments, LABWorld China responds to the rapid growth in the number of participants focused on high technology areas such as instrumental analysis, measuring and testing technologies, materials testing, quality control and laboratory equipment.
Innopack China
China’s leading dedicated pharma packaging event, Innopack China , is part of CPhI/P-MEC China. The event is dedicated to bringing global packaging solution providers and their latest innovations to the Chinese pharmaceutical community, offering a forum for business development, networking, brand promotion and education.
As Chinese pharma manufacturers are increasingly seeking more sophisticated and reliable packaging solutions to deal with the rapid-changing demand of the global pharma market, Innopack China brings together quality suppliers and focused buyers.
BioPh China
BioPh offers a natural business platform to the world of pharma, focusing on biopharmaceutical development and services, both face to face and online.
Companies and organizations dealing with the research and development of new treatment methods made through biotechnological processes or which are derived from or use live organisms will benefit from exhibiting at BioPh.
Thanks to the influence of traditional Chinese medicine culture, Chinese plant extract industry has unique developing advantages. China is now regarded as an important international natural extract ingredient supplier. They have achieved this status by combining resource utilization with competitive pricing. Of all the natural extract categories, plant extracts and medicinal herbs have become the most well known. This is due to a mixture of China's access to vast territories with abundant plant resources, and their centuries of traditional Chinese medicine development. Currently there are over 2,000 companies manufacture and trade of plant extracts in the country.
The Natural Extract Area (NEA) brings a great selection of those companies, expected to bring over 300 extract suppliers to the event.
The CPhI 2012 event
More than 29,000 attendees visited CPhI China in 2012, eclipsing the global pharmaceutical event’s 2011 turnout by more than 2,000 people. The event grew seven per cent over 2011 figures and also saw a 16.5 per cent increase in exhibitors.
The China-World Forum, Biopharmaceutical Engineering Forum, Drug Safety Workshop and the API Prequalification Seminar all recorded strong attendance during the event. The second edition of the CPhI Buyers Sourcing Event was also successful, with 106 meetings covering over 451 product categories.
UBM Live’s China pharma events portfolio provides a unique platform for visitors to network with existing and new clients, compare products, and learn about newest market trends and opportunities. For visitors, the events are a key meeting place for the pharmaceutical industry to do business in a format that has exceptional ROI on travel budgets and time. For exhibitors, the events offer unrivalled potential to showcase their expertise, products and services, meet potential partners for future collaborations and generate new revenue streams.
CPhI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market.